S-1/A: Evoke Pharma Announces Proposed Public Offering of Common Stock and Warrants

Evoke Pharma is seeking to raise capital through a public offering of common stock units and pre-funded warrant units to fund operations and commercialization activities.

Summary

• Evoke Pharma has filed an amendment to its registration statement for a proposed public offering.
• The offering includes up to 10,000,000 common stock units, each containing one share of common stock and Series A, B, and C warrants.
• The assumed purchase price is $0.75 per common stock unit, based on the last sale price on February 6, 2024.
• The company is also offering pre-funded warrant units (PFW Units) as an alternative for purchasers who would exceed a 4.99% ownership threshold.
• Each PFW Unit consists of a pre-funded warrant and Series A, B, and C warrants.
• The exercise price for the pre-funded warrants is $0.0001 per share.
• The Series A and C warrants will have an exercise price of $ per share, while the Series B warrants will have an exercise price equal to 100% of the price per Common Stock Unit.
• The Series A warrants expire five years from the closing date, while the Series B and C warrants expire nine months from the closing date, with a potential extension for Series C warrants if corresponding Series B warrants are exercised.
• Evoke Pharma intends to use the net proceeds for working capital, general corporate purposes, and potentially to acquire or in-license complementary businesses or products.
• As of December 31, 2023, Evoke Pharma estimates having approximately $4.7 million in cash and cash equivalents.

Sentiment

Score: 4

Explanation: The document is largely neutral, providing factual information about the proposed offering. However, the company's financial situation and dependence on a single product temper the outlook, resulting in a slightly negative sentiment.

Positives

• The offering could provide Evoke Pharma with necessary capital to fund its operations and commercialization efforts.
• The inclusion of warrants may make the offering more attractive to investors.
• The potential use of proceeds for acquisitions or in-licensing could expand Evoke Pharma's product pipeline.

Negatives

• The company has incurred losses every year since its inception and expects to continue to incur operating losses until revenues from the sales of Gimoti exceed expenses, if ever.
• The company's business is entirely dependent on the success of Gimoti, which may never generate sufficient sales to become profitable.
• The company may be required to liquidate, dissolve or otherwise wind down operations if it is unable to secure additional financing, successfully commercialize Gimoti or identify and execute on other commercialization or strategic alternatives for Gimoti or the Company.
• The company has a very limited number of remaining unreserved and authorized shares available for issuance, which will impact its ability to raise additional funds in the future.
• The company may not receive any additional funds upon the exercise of the Pre-Funded Warrants or Common Warrants.

Risks

• Evoke Pharma's business is entirely dependent on the success of Gimoti.
• The company will require substantial additional funding and may be unable to raise capital when needed.
• Evoke Pharma relies on Eversana for the commercialization of Gimoti, and termination of that agreement could negatively impact sales.
• The company faces substantial competition in the market.
• The company's recurring losses from operations have raised substantial doubt regarding its ability to continue as a going concern.
• The company may fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist the company's common stock, the delisting could adversely affect the market liquidity of the company's common stock and the market price of the company's common stock could decrease.

Future Outlook

Evoke Pharma believes that its cash and cash equivalents, future cash flows from net sales of Gimoti, and the net proceeds from this offering will be sufficient to fund operations for at least the next twelve months. The company plans to continue commercializing Gimoti, further develop Gimoti with a lower dosage strength, seek partnerships, and in-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases.

Industry Context

The document mentions the potential impact of increased use of GLP-1 agonists on the gastroparesis market, as these agonists can cause slowed gastric emptying, potentially leading to symptoms similar to gastroparesis. The document cites a study published in the Journal of the American Medical Association that found an association between GLP-1 agonists for weight loss and an increased risk of gastroparesis.

Related Party Transactions

• In 2020, Evoke Pharma borrowed $5 million from Eversana pursuant to a revolving credit facility.
• As of September 30, 2023, there were approximately $60.4 million in cumulative unreimbursed commercialization costs under the agreement with Eversana.

Stakeholder Impact

• The offering will dilute existing shareholders' ownership.
• The success of the offering and subsequent use of proceeds will impact the company's ability to continue operations and commercialize Gimoti, affecting employees, customers, and suppliers.
• The company's ability to repay its debt obligations will impact its creditors.

Next Steps

• Evoke Pharma will determine the final pricing and terms of the offering.
• The company will seek to complete the public offering.
• Evoke Pharma will use the net proceeds for working capital, general corporate purposes, and potential acquisitions or in-licensing.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Gimoti, Evoke Pharma, financing, gastroparesis, pharmaceutical, commercialization